MaaT Pharma MAAT
EURONEXT · France · Health Technology
€1.03-0.05 (-4.98%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
LYON, France, September 29, 2026--MaaT Pharma Publishes its Half-Year 2026 Results and Provides a Business Update
LYON, France, September 21, 2026--MaaT Pharma Announces Upcoming Pre-IND Meeting with the FDA and Advances MaaT034 Toward Clinical Development in Solid Tumors
LYON, France, September 18, 2026--MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination
LYON, France, September 15, 2026--MaaT Pharma Receives Negative CHMP Trend Vote for MaaT013 Following Re-Examination for its Conditional Marketing Authorization Application in Europe
Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Microbiome Therapeutics Market by Type of Product, Route of Administration, Target Indication, Therapeutic Area, End User and Geographical Regions - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global microbiome therapeutics market is projected to increase from USD 0.6 billion in 2026 to USD 4.6 billion by 2035, registering a compound annual growth rate of 25.4% during the forecast period. Market expansion
LYON, France, July 06, 2026--MaaT Pharma Presents the Results of its Annual General Meeting and Provides a Statement on its Half-Year Liquidity Contract.
LYON, France, July 02, 2026--Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
LYON, France, June 26, 2026--MaaT Pharma Announces Plan to Request Re-Examination Following Negative CHMP Opinion for MaaT013 for the treatment of acute Graft-versus-Host Disease
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.